Researchers have developed a new intravaginal ring for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a contraceptive. Tenofovir is the only topical prophylactic shown to be effective at reducing the sexual transmission of HIV when formulated in a gel. Read more.
![](https://www.myamericannurse.com/wp-content/uploads/2014/07/happy-couple.jpg)
New intravaginal ring
Share